Volume rendered 3D OCTA assessment of macular ischemia in patients with type 1 diabetes and without diabetic retinopathy.
Adult
Aged
Diabetes Mellitus, Type 1
/ complications
Diabetic Retinopathy
/ diagnosis
Female
Humans
Image Processing, Computer-Assisted
Imaging, Three-Dimensional
Ischemia
/ diagnostic imaging
Macula Lutea
/ blood supply
Male
Middle Aged
Retinal Vessels
/ diagnostic imaging
Retrospective Studies
Tomography, Optical Coherence
/ methods
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 10 2021
05 10 2021
Historique:
received:
23
08
2021
accepted:
09
09
2021
entrez:
6
10
2021
pubmed:
7
10
2021
medline:
28
12
2021
Statut:
epublish
Résumé
The aim of this study was to measure macular perfusion in patients with type 1 diabetes and no signs of diabetic retinopathy (DR) using volume rendered three-dimensional (3D) optical coherence tomography angiography (OCTA). We collected data from 35 patients with diabetes and no DR who had OCTA obtained. An additional control group of 35 eyes from 35 healthy subjects was included for comparison. OCTA volume data were processed with a previously presented algorithm in order to obtain the 3D vascular volume and 3D perfusion density. In order to weigh the contribution of different plexuses' impairment to volume rendered vascular perfusion, OCTA en face images were binarized in order to obtain two-dimensional (2D) perfusion density metrics. Mean ± SD age was 27.2 ± 10.2 years [range 19-64 years] in the diabetic group and 31.0 ± 11.4 years [range 19-61 years] in the control group (p = 0.145). The 3D vascular volume was 0.27 ± 0.05 mm
Identifiants
pubmed: 34611239
doi: 10.1038/s41598-021-99297-7
pii: 10.1038/s41598-021-99297-7
pmc: PMC8492730
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19793Informations de copyright
© 2021. The Author(s).
Références
Acta Ophthalmol. 2017 Dec;95(8):e751-e755
pubmed: 28211261
Sci Rep. 2019 Nov 14;9(1):16789
pubmed: 31728070
Br J Ophthalmol. 2019 Feb;103(2):216-221
pubmed: 29706601
Retina. 2017 Jan;37(1):11-21
pubmed: 27557084
Curr Med Chem. 2013;20(26):3218-25
pubmed: 23745544
Acta Ophthalmol. 2018 Mar;96(2):e264-e265
pubmed: 28887911
IEEE Trans Med Imaging. 2020 May;39(5):1335-1346
pubmed: 31647423
Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):2167-2176
pubmed: 29801151
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):190-196
pubmed: 28114579
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5101-5106
pubmed: 27699408
J Biophotonics. 2020 Oct;13(10):e202000152
pubmed: 32526048
Br J Ophthalmol. 2020 Feb;104(2):162-166
pubmed: 31036586
Prog Retin Eye Res. 2018 Nov;67:30-55
pubmed: 30059755
Prog Retin Eye Res. 2018 May;64:1-55
pubmed: 29229445
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Ophthalmol Ther. 2019 Jun;8(2):215-226
pubmed: 30868418
Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):231-237
pubmed: 29340651
Retina. 2021 Aug 1;41(8):1660-1667
pubmed: 33332812
Sci Rep. 2019 Nov 19;9(1):17053
pubmed: 31745216
Retina. 2015 Nov;35(11):2364-70
pubmed: 26469537
Sci Rep. 2020 Jan 21;10(1):800
pubmed: 31964977
Br J Ophthalmol. 2020 Dec 22;:
pubmed: 33355147
Ophthalmology. 2019 Dec;126(12):1675-1684
pubmed: 31358386
Am J Ophthalmol. 2013 Oct;156(4):684-92
pubmed: 23891332
Retina. 2017 Mar;37(3):424-435
pubmed: 27749698
Acta Diabetol. 2017 Jul;54(7):695-702
pubmed: 28474119
Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):53
pubmed: 32866267